⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
about
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?Advancing biomedical imagingProstate-specific membrane antigen as a target for cancer imaging and therapyIndium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89.Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modelingEvaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice.Applications of indocyanine green in robotic urology.Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.Immuno-PET for Clinical Theranostic Approaches.Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.Next revolution in molecular theranostics: personalized medicine for urologic cancers.Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts.VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man.First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.Radiochemistry and Preclinical PET Imaging of 68Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen.Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer.Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma.Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.
P2860
Q26744088-ADA0E9DA-3C11-4E82-A0A7-03C2CA8C9091Q26776383-7BC4E278-9BA9-4141-A12B-8A5A8B1D0F17Q26799439-627510A7-2E50-4024-9F2E-C4FFD2C5E276Q35587920-DED077BA-C31D-4708-AC95-7C5B1434CC27Q35865849-4FE2F0D6-3A39-4A6A-8A57-CD4C25FC789EQ36491493-F1DF2113-E9C6-4B83-A863-D399BC6CF55CQ36644332-D25AB67D-2496-4EB2-9AE9-A33812EADD5CQ37413533-BCDCB621-8B01-4DAF-8F4C-F8523DE079B1Q37554230-EB1567DA-23F8-4A51-AB0F-42B152D0ECE4Q37631461-A64CDAB1-AA65-4228-9BDB-DAC2E26718A9Q37722443-D4896818-AB30-4F23-806C-A4A2F699C7E2Q38559336-8A9EE3C4-BA25-44AC-84C5-7F377AAE3905Q38791259-B5A13091-7575-485C-9A15-57B8BD02A96CQ38948710-713C5029-B635-4DDD-9C04-980501399907Q40625131-65D88823-2756-4D1C-80D4-E8EB2D2508F3Q40735810-77E51C81-1790-4B01-8A38-D9EC421EEAA9Q42328242-3BD24E9B-95DF-45FD-9202-EC3383B4715BQ45753373-D23AF9DA-18D2-4435-868F-1C6D1119BBF0Q47097395-B4D15011-C297-4602-BE2F-5AF0C6704A05Q47965803-20982B96-7676-4C2F-A544-32A24DC4E5FEQ48136353-A7D023E7-1DBA-4F6B-A5E4-144B17AA1B9CQ50034009-4F7C95B4-2448-45E1-8860-9CC16BE88FFFQ50571860-1A17B915-CDBB-43EB-8F56-CFAA8E23667CQ52672750-75822FCF-85C6-4CF0-AB31-4CE38D2D721AQ52983334-492E8CA9-A898-4F46-9BF4-8CED76980138
P2860
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
@en
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
@nl
type
label
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
@en
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
@nl
prefLabel
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
@en
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
@nl
P2093
P2860
P50
P1476
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
@en
P2093
Howard I Scher
Massimo F Loda
Mithat Gonen
Neeta Pandit-Taskar
Neil H Bander
Peter M Smith-Jones
Robert A Lefkowitz
Sarah M Cheal
Serge Lyashchenko
Shutian Ruan
P2860
P2888
P304
P356
10.1007/S00259-014-2830-7
P50
P577
2014-08-21T00:00:00Z